Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Revenue (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Revenue for 6 consecutive years, with $243.8 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 21.12% to $243.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $868.5 million through Dec 2025, up 21.51% year-over-year, with the annual reading at $868.5 million for FY2025, 21.51% up from the prior year.
  • Revenue hit $243.8 million in Q4 2025 for Harmony Biosciences Holdings, up from $239.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $243.8 million in Q4 2025 to a low of $59.7 million in Q1 2021.
  • Historically, Revenue has averaged $145.4 million across 5 years, with a median of $144.4 million in 2023.
  • Biggest five-year swings in Revenue: surged 200.78% in 2021 and later grew 16.01% in 2025.
  • Year by year, Revenue stood at $91.2 million in 2021, then soared by 40.67% to $128.3 million in 2022, then soared by 31.26% to $168.4 million in 2023, then rose by 19.51% to $201.3 million in 2024, then increased by 21.12% to $243.8 million in 2025.
  • Business Quant data shows Revenue for HRMY at $243.8 million in Q4 2025, $239.5 million in Q3 2025, and $200.5 million in Q2 2025.